French pharmaceutical company Sanofi revealed on Tuesday its partnership with artificial intelligence firm OpenAI and Formation Bio, aiming to enhance its drug development endeavors through the utilization of AI technology.
In an official statement, Sanofi highlighted that teaming up with OpenAI will grant them access to exclusive data for the development of AI models tailored for their biopharmaceutical projects.
Additionally, Formation Bio will contribute supplementary engineering resources to support these efforts.
The collaboration underscores a growing trend among major pharmaceutical companies leveraging artificial intelligence to streamline various aspects of drug development.
Specifically, AI is being employed to swiftly identify suitable candidates for clinical trials and to optimize the testing process, thereby expediting the overall drug development timeline and potentially yielding substantial cost savings amounting to millions of dollars.
This strategic partnership reflects Sanofi’s commitment to harnessing cutting-edge technology to advance its drug discovery and development initiatives, with the aim of bringing innovative therapies to patients in need more efficiently and effectively.
